Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens

Sánchez-Sampedro, Lucas; Gómez, Carmen Elena; Mejías-Pérez, Ernesto; Pérez-Jiménez, Eva; Oliveros, Juan Carlos; Esteban, Mariano

doi:10.1128/jvi.03013-12

Cited by 12 publications

(10 citation statements)

References 76 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent computational effort has gone up to the strain level comparison and considered proteins as vaccine targets that were shared among tuberculoid, non-tuberculoid, and vaccine strains ( 16 ). Continuous efforts are being made by researchers to identify novel vaccine candidates against several pathogens such as Ebola virus ( 14 ), Zika virus ( 15 ), vaccinia virus ( 38 ), Neisseria meningitidis ( 39 ), Corynebacterium pseudotuberculosis ( 40 ) Edwardsiella tarda , and Flavobacterium columnare ; fish pathogens ( 41 , 42 ).…”

Section: Discussionmentioning

confidence: 99%

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria

2018

View full text Add to dashboard Cite

Evolution has led to the expansion of survival strategies in pathogens including bacteria and emergence of drug resistant strains proved to be a major global threat. Vaccination is a promising strategy to protect human population. Reverse vaccinology is a more robust vaccine development approach especially with the availability of large-scale sequencing data and rapidly dropping cost of the techniques for acquiring such data from various organisms. The present study implements an immunoinformatic approach for screening the possible antigenic proteins among various pathogenic bacteria to systemically arrive at epitope-based vaccine candidates against 14 pathogenic bacteria. Thousand four hundred and fifty nine virulence factors and Five hundred and forty six products of essential genes were appraised as target proteins to predict potential epitopes with potential to stimulate different arms of the immune system. To address the self-tolerance, self-epitopes were identified by mapping on 1000 human proteome and were removed. Our analysis revealed that 21proteins from 5 bacterial species were found as virulent as well as essential to their survival, proved to be most suitable vaccine target against these species. In addition to the prediction of MHC-II binders, B cell and T cell epitopes as well as adjuvants individually from proteins of all 14 bacterial species, a stringent criteria lead us to identify 252 unique epitopes, which are predicted to be T-cell epitopes, B-cell epitopes, MHC II binders and Vaccine Adjuvants. In order to provide service to scientific community, we developed a web server VacTarBac for designing of vaccines against above species of bacteria. This platform integrates a number of tools that includes visualization tools to present antigenicity/epitopes density on an antigenic sequence. These tools will help users to identify most promiscuous vaccine candidates in a pathogenic antigen. This server VacTarBac is available from URL (http://webs.iiitd.edu.in/raghava/vactarbac/).

show abstract

Section: Discussionmentioning

confidence: 99%

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria

2018

View full text Add to dashboard Cite

show abstract

“…Although both mutants were able to induce protection in mice challenged by L. major, they did not induce protection against L. amazonensis infection. Protection was similar to that triggered by MVA-LACK [50]. Nevertheless, the protocol of DNA-LACK prime/ MVA-LACK or M65-LACK virus boost vaccination significantly reduced the parasite load in the liver and bone marrow of hamsters challenged by L. infantum, with no differences recorded between the use of MVA or M65 virus vector options [51].…”

Section: Vaccinia Virus In Leishmaniases Vaccines Developmentmentioning

confidence: 94%

Vaccinia Virus-Derived Vectors in Leishmaniases Vaccine Development

Oliveira¹,

Campos²,

Silva³

et al. 2019

Vaccines - The History and Future

View full text Add to dashboard Cite

Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the diseases has become a high priority. The development of vaccines against the various species of pathogenic Leishmania to humans has been hampered, in part, by the inefficient stimulation of the protective cellular immunity promoted by the administration of purified or recombinant antigens, indicating the need for new approaches. Viral vectors represent an attractive way to deliver and present vaccine antigens that may offer advantages over traditional platforms. Among the most attractive and efficient viral vectors in inducing a cellular immune response, vaccinia virus has been the most used in leishmaniases vaccine trials. The first report of the use of recombinant vaccinia virus (VACV) in the induction of protection against Leishmania infection was made in 1993. Since then, several Leishmania spp. antigenic subunits were cloned into recombinant VACV. Although highly attenuated poxviral vectors are capable of inducing protective immunity against Leishmania spp., their limitation in replicative capacity reduces their potential as compared to replicative vectors. In order to achieve a balance between safety and replication, several VACV strains with intermediate phenotype have been developed.

show abstract

“…114,115 Other attenuated replication competent vectors are M65 and M101, derived from the Western Reserve (WR) strain after multiple passages in Friend erytroleukemia cells, that have been shown to contain mutations in multiple gene sequences but with the capacity to trigger immunogenicity and protection against leishmania parasitic infection. 116 Another replication-competent and attenuated smallpox-derived vaccines, such as the Japanese LC16m8 (derived from the Lister vaccinia strain), [117][118][119] and the Chinese Tian-Tan strains 111,120,121 are also being investigated as vaccines for other diseases. Moreover, myxomavirus have been used as a promising vaccine candidate against several types of cancer, due to the oncolytic ability of this poxvirus to specifically infect various classes of human cancer cells.…”

Section: Enhancing Vector Replication Capacitymentioning

confidence: 99%

Enhancing poxvirus vectors vaccine immunogenicity

García-Arriaza

Esteban

2014

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

A ttenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens are currently at various stages in clinical trials with the aim to establish their efficacy. This is because these vectors have shown excellent safety profiles, significant immunogenicity against foreign expressed antigens and are able to induce protective immune responses. In view of the limited efficacy triggered by some poxvirus strains used in clinical trials (i.e, ALVAC in the RV144 phase III clinical trial for HIV), and of the restrictive replication capacity of the highly attenuated vectors like MVA and NYVAC, there is a consensus that further improvements of these vectors should be pursuit. In this review we considered several strategies that are currently being implemented, as well as new approaches, to improve the immunogenicity of the poxvirus vectors. This includes heterologous prime/ boost protocols, use of co-stimulatory molecules, deletion of viral immunomodulatory genes still present in the poxvirus genome, enhancing virus promoter strength, enhancing vector replication capacity, optimizing expression of foreign heterologous sequences, and the combined use of adjuvants. An optimized poxvirus vector triggering longlasting immunity with a high protective efficacy against a selective disease should be sought.

show abstract

Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens

Cited by 12 publications

References 76 publications

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria

Vaccinia Virus-Derived Vectors in Leishmaniases Vaccine Development

Enhancing poxvirus vectors vaccine immunogenicity

Contact Info

Product

Resources

About